drugset
drugset / Trial / NCT03526887

Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC

NCT03526887 ↗

Phase 2 Completed 73 enrolled Spanish Lung Cancer Group
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Exploratory phase II trial of intravenous (IV) Pembrolizumab MK-3475 as second or further line with advanced Non-small cell Lung Cancer (NSCLC) who have failed to a prior treatment with anti-PDL1 drug. Pembrolizumab 200 mg ,Q3W, IV infusion, Day 1 of each 3 week cycle will be administered until disease progression.

Timeline

Start
2018-07-15
Primary completion
2022-12-30
Completion
2023-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

lung cancer